NDAORALTABLET
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VICOPROFEN is a fixed-dose combination oral tablet combining hydrocodone bitartrate (an opioid analgesic) with ibuprofen (an NSAID) approved in 1997. It is indicated for short-term management of acute pain where the combination of an opioid and NSAID is appropriate. The dual mechanism provides synergistic analgesia through opioid receptor agonism and cyclooxygenase inhibition.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), signaling potential team restructuring and transition planning activities within the brand organization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VICOPROFEN offers limited career growth opportunities given its LOE-approaching lifecycle and minimal linked job availability. Roles focus on defensive brand management, generic competition mitigation, and compliance rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on VICOPROFEN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.